Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: BishopsChild who wrote (460)	3/17/2000 10:39:00 AM
From: Skywatcher	Read Replies (1) \| Respond to of 1137

SciClone Receives Three New Zadaxin(R) Marketing Approvals SAN MATEO, Calif., March 17 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news) today announced that ZADAXIN, the Company's lead immunotherapy, has been approved for marketing in Thailand, Laos and Malta. ZADAXIN now is approved for marketing in 19 countries, principally for treatment of hepatitis B and hepatitis C. SciClone has filed for ZADAXIN marketing approval in 18 additional countries. Hepatitis B and hepatitis C are highly infectious liver diseases that can lead to cirrhosis, liver cancer and death. Worldwide, there are approximately 350 million long-term carriers of the hepatitis B virus, including approximately 1.2 million in the U.S. Approximately 170 million people worldwide are infected with the hepatitis C virus, including 4 million in the U.S. and 5 million in Europe. Many patients with cancer and chronic infectious diseases have an impaired immune system. ZADAXIN significantly enhances the immune system's ability to recognize and destroy cancerous and infected cells. ZADAXIN immunotherapy is in late-stage development for cancer and viral hepatitis worldwide. CHRIS